West Nile Virus Update – Interpretation of serology results and investigation of cases with neurological involvement

To Health Care Providers:

This Labstract provides:

2. An update on confirmatory Plaque Reduction Neutralization Test (PRNT) testing of positives in health regions.
3. An update on recommended laboratory investigations and specimen requirements for cases of suspected WNV infection and cases with neurological involvement.

1. Interpretation of WNV serological test results (refer to Table 1)

Enzyme-linked Immunosorbent Assays (ELISAs)
The WNV IgM and IgG Enzyme–Linked Immunosorbent Assays (ELISAs) are used as screening tests: a reactive IgM antibody response using ELISA is specific for WNV and is rarely due to cross-reaction with other flaviviruses.

- If a patient has recently travelled to an area endemic for flaviviruses other than WNV, please document this on the laboratory requisition and contact the laboratory to request any follow up investigations if they are WNV IgM positive.
- Any recent tick bites (the vector for Powassan virus, which is endemic in Ontario) should be documented.
- A reactive IgG antibody response using ELISA may be due to infection with WNV or other flaviviruses, (e.g. dengue, St. Louis encephalitis, Japanese encephalitis, Powassan, or yellow fever virus) which may cross react.

Specimen Requirements and test ordering
Acute and convalescent serology (clotted blood or serum) should be submitted to confirm a recent infection.

When ordering serology:

- Use a Public Health Ontario Laboratory (PHOL) requisition form and enter “West Nile Virus” under test description
- Indicate that the test is for suspect West Nile Virus, symptoms, date of any significant mosquito exposures, symptom onset date, any travel history, and whether the test is for acute or convalescent serology testing.
West Nile Virus Update – Interpretation of serology results and investigation of cases with neurological involvement (Continued)

2. Confirmatory PRNT testing of positives in health regions

Plaque Reduction Neutralization Test (PRNT)
All early season IgM reactive samples will be further tested using the confirmatory plaque reduction neutralization test (PRNT) which is highly specific for WNV. However, PRNT testing is not necessary to make a diagnosis of WNV infection once WNV season is established within the local health region (3 positive PRNT results in an individual health region), at which time a reactive IgM ELISA test is sufficient for laboratory confirmation. In addition, repeat PRNT testing may not be performed if a patient has had a previous reactive PRNT test.

Indeterminate results for any of the WNV assays may be due to the presence of low-level antibodies or non-specific reactions. Therefore, as with all laboratory tests, the results should be interpreted in the context of the clinical history.

Note: During the summer season samples which are IgG positive and IgM negative will not be further tested by PRNT as this indicates a past flavivirus infection, more than several months ago. If further investigation of these samples is required please contact the Customer Service Centre and ask to speak to the microbiologist.

3. Update on recommended laboratory investigations and specimen requirements for cases of suspected West Nile Virus infection and cases with neurological involvement

For specimen requirements, in addition to clotted blood or serum acute and convalescent serology, submit a CSF sample for serological testing (WNV IgM), which is reactive in the majority of patients with WNV neuroinvasive disease. A positive CSF WNV IgM is sufficient for laboratory confirmation of CNS WNV infection.

Although WNV PCR testing is available, it is not considered a first line test as it is less sensitive than CSF IgM ELISA due to the brief viremia experienced in WNV infection. Please note that PCR testing is not required to confirm the diagnosis, and usually is not necessary. However, under special circumstances, the National Microbiology Laboratory (NML) can perform WNV PCR testing on patients with suspected neuroinvasive disease who are WNV IgM positive. Contact the Customer Service Centre and ask to speak to a microbiologist to request CSF PCR testing.
**West Nile Virus Update – Interpretation of serology results and investigation of cases with neurological involvement (Continued)**

**Table 1: Interpretation of WNV Laboratory Tests**

<table>
<thead>
<tr>
<th>IgM ELISA</th>
<th>IgG ELISA</th>
<th>PRNT</th>
<th>Interpretation of WNV Tests</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-reactive</td>
<td>Non-reactive</td>
<td>Not tested</td>
<td>No serological evidence of recent or past WNV infection.</td>
</tr>
<tr>
<td>Non-reactive</td>
<td>REACTIVE</td>
<td>Not tested</td>
<td>Probable past WNV and/or other flavivirus infection or vaccination against a non-WNV flavivirus (e.g. yellow fever and Japanese encephalitis virus). PRNT testing is not warranted.</td>
</tr>
<tr>
<td>REACTIVE or Indeterminate</td>
<td>REACTIVE</td>
<td>REACTIVE ≥1:40</td>
<td>Consistent with recent or past WNV infection. IgM antibodies may persist for &gt;1 year at low levels and may be indicative of a previous infection.</td>
</tr>
<tr>
<td>REACTIVE</td>
<td>Non-reactive or Indeterminate</td>
<td>REACTIVE ≥1:40</td>
<td>Consistent with recent or acute WNV infection. A follow-up serum sample in two weeks is recommended to demonstrate the development of IgG antibodies. The failure to develop IgG antibodies suggests possible cross-reactive antibodies from another flavivirus infection.</td>
</tr>
<tr>
<td>REACTIVE</td>
<td>REACTIVE</td>
<td>Non-reactive or Indeterminate</td>
<td>Probable recent or past WNV infection. A follow-up serum sample in two weeks is recommended to demonstrate the development of IgG antibodies. The failure to develop IgG antibodies suggests a non-specific IgM reaction.</td>
</tr>
<tr>
<td>Indeterminate</td>
<td>REACTIVE</td>
<td>Non-reactive or Indeterminate</td>
<td>Probable past flavivirus infection or vaccination. The IgG ELISA cannot differentiate between members of the Flavivirus genus. A follow-up serum sample in two weeks is recommended, as well as consideration for testing for other flaviviruses, depending on the clinical history.</td>
</tr>
<tr>
<td>Indeterminate</td>
<td>Indeterminate</td>
<td>Not tested</td>
<td>West Nile Virus antibody status inconclusive. A follow-up serum sample in two weeks is recommended. Persistent indeterminate results for WNV IgM and IgG antibodies suggest a non-specific reaction.</td>
</tr>
</tbody>
</table>

* Avidity testing may be considered in order to differentiate recent (last few months) from remote infections. This should only be considered in patients with severe illness (e.g. hospitalized).

** Once WNV activity is established in a health region, PRNT testing will no longer be performed for the remainder of the season.
West Nile Virus Update – Interpretation of serology results and investigation of cases with neurological involvement (Continued)

For further information:

- Contact the PHOL Customer Service Centre at 416-235-6556 or 1-877-604-4567 (toll-free) or by email at CustomerServiceCentre@oahpp.ca
- For the PHOL Specimen Collection Guide and previous Labstracts, refer to http://www.oahpp.ca/services/public-health-laboratories.html
- The current version of the PHO laboratory requisition form is available at http://www.oahpp.ca/resources/requisitions.html
- To subscribe to future Labstracts, email labstracts@oahpp.ca
- To register for Autofax and receive PHL reports by fax directly from our laboratory information system as soon as they are released, contact the PHOL Customer Service Centre.